Introduzca una acción o criptomoneda en el cuadro de búsqueda para obtener un resumen
Lepu Biopharma Co Ltd
2157Lepu Biopharma Co., Ltd., a biopharmaceutical company, focuses on the discovery, development, and commercialization of drugs for cancer targeted therapy and immunotherapy in China and internationally. The company offers PUYOUHENG (Pucotenlimab Injection), a humanized IgG4 mAb against human PD-1 for the treatment of solid tumors and melanoma. It is also developing MRG003 that is in phase III clinical study for treating nasopharyngeal cancer, and head and neck squamous cell carcinoma; and MRG002, which is in phase III trials to treat breast and urothelial cancer, as well as HER2-positive. In addition, the company is developing MRG001 CD20-targeted ADC for treating non-Hodgkin's lymphoma; CMG901 CLDN18.2-targeted ADC for treating gastric and gastroesophageal junction carcinoma and other solid tumors; and MRG004A TF-targeted ADC for treating advanced or metastatic solid tumors. Further, it is developing CG00705 Oncolytic virus for treating bacillus calmette-guerin unresponsive non-muscle invasive bladder cancer; and MRG006A and CTM012 for the treatment of solid tumors. The company was incorporated in 2018 and is headquartered in Shanghai, China. Address: No. 651, Lianheng Road, Shanghai, China, 201612
Analytics
Precio Objetivo de WallStreet
38.92 HKDRelación P/E
–Rentabilidad por dividendo
–Año en curso
Año anterior
Trimestre actual
Último trimestre
Año en curso
Año anterior
Trimestre actual
Último trimestre
Cifras clave 2157
Análisis de dividendos 2157
Aumento del dividendo durante 5 años
–Crecimiento continuo
–Ratio de pago medio en 5 años
–Tendencia del payout 2157
Valoración de la acción 2157
Finanzas 2157
Realice un seguimiento de las métricas clave de cada acción en un solo lugar y sin complicaciones
Hazte premiumResultados | 2019 | Dinámica |